Skip to main content

Correction to: The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma

The Original Article was published on 27 February 2018

Erratum

The original article [1] contained an error whereby Fig. 4 displayed incorrect magnification scales.

Fig. 4
figure 1

Morphological and functional effects of TINO when combined with RT in glioma cell lines. a Morphological changes observed in U251 cells after treatments with 2, 4, and 6 Gy (RT) alone or in association with TINO 3.5 μM. b Morphological changes observed in U87MG cells after treatments with 2, 4, and 6 Gy (RT) alone or in association with TINO 3.5 μM. c Representative expression of acidic vacuolar organelle (AVO) accumulation in T98G cells cultured with 2, 4, and 6 Gy (RT) alone or in association with TINO 3.5 μM. d Percentage of AVO-stained cells in U87MG, U251, and T98G cells cultured with 2, 4, and 6 Gy (RT) alone or in association with TINO 3.5 μM. Statistical analysis: *p < 0.005 in the comparison between combined TINO + RT treatment and RT alone. Single results are representative of three different experiments performed in triplicate. e Immunocytochemical evaluation of γH2Ax stain in T98G cells cultured with 4, 6, and 8 Gy (RT) alone or in association with TINO 3.5 μM. f Quantization of γH2AX expression in U87MG, U251, and T98G cells treated with RT with or without TINO. Statistical analyses: *p < 0.005 in the comparison between RT + TINO and RT or TINO treatments alone. Single results are representative of three different experiments performed in triplicate

This has now been corrected, and can be seen ahead and in the original article [1].

Reference

  1. Festuccia C, et al. The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma. J Hematol Oncol. 2018;11:32.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to C. Festuccia.

Additional information

The original article can be found online at https://doi.org/10.1186/s13045-018-0576-6.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Festuccia, C., Mancini, A., Colapietro, A. et al. Correction to: The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma. J Hematol Oncol 11, 38 (2018). https://doi.org/10.1186/s13045-018-0587-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13045-018-0587-3